Epitope characterization of MUC1 antibodies

被引:20
|
作者
Blockzjil, A [1 ]
Nilsson, K [1 ]
Nilsson, O [1 ]
机构
[1] CanAg Diagnost AB, SE-41455 Gothenburg, Sweden
关键词
MUC1; epitope specificity; CA; 15-3; pepscan analysis; TD-4;
D O I
10.1159/000056504
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The specificities of the 56 MAbs submitted to the ISOBM TD-4 Workshop were characterized by ELISA assays against MUC1-positive (ZR75-1) and MUC1-negative cell lines (LS174T), binding to a 20-mer peptide corresponding to the tandem repeat region of MUC1! apoprotein, and Pepscan analysis of overlapping 9-mer peptides corresponding to the tandem repeat region of MUC1., The recognition of soluble MUC1 antigen from ZR75-1 cell line was also tested in two-site EIA using the ISOBM TD-4 MAb as catching MAb, The studies indicated that 35 of the submitted antibodies recognized epitopes expressed in the MUC1 tandem repeat region, and that 30 of these recognized epitopes within the immunodominant region (PDTRPAP) of the tandem repeat, Recognition of soluble MUC1 from ZR75-1 cell line indicated that additional 10 MAb recognized epitopes 'outside' the tandem repeat region of MUC1 from ZR75-1 cell line, or that the antibodies recognized epitopes depending on the glycosylation of the MUC1 tandem repeat. Six MAbs reacted only with the MUC1-negative cell line LS 174T, and thus most likely did not recognize epitopes specific for MUC1.
引用
收藏
页码:46 / 56
页数:11
相关论文
共 50 条
  • [21] Tolerance and immunity to MUC1 in a human MUC1 transgenic murine model
    Rowse, GJ
    Tempero, RM
    VanLith, ML
    Hollingsworth, MA
    Gendler, SJ
    CANCER RESEARCH, 1998, 58 (02) : 315 - 321
  • [22] Mimic 1 of MUC1
    Finn, OJ
    Gendler, SJ
    NATURE BIOTECHNOLOGY, 1998, 16 (03) : 236 - 237
  • [23] Mimic 1 of MUC1
    Olivera J. Finn
    Sandra J. Gendler
    Nature Biotechnology, 1998, 16 : 236 - 237
  • [24] Tolerance and immunity to MUC1 in a human MUC1 transgenic murine model
    Tempero, RM
    Morikane, K
    Vanlith, ML
    Gendler, SJ
    Hollingsworth, MA
    FASEB JOURNAL, 1998, 12 (05): : A891 - A891
  • [25] Monoclonal antibodies against the nonmucin domain of institute MUC1/episialin
    Hilkens, J
    Boer, M
    TUMOR BIOLOGY, 1998, 19 : 67 - 70
  • [26] Targeting the MUC1-SEA Module With Antibodies for Ablating Human MUC1 Positive Cancer Cells
    Pichinuk, Edward
    Wreschner, Daniel
    JOURNAL OF IMMUNOTHERAPY, 2011, 34 (02) : 224 - 224
  • [27] Inhibiting MUC1 a/b chain interaction mediates cytotoxicity of cells expressing MUC1: The MUC1 dyad oncoprotein as a functional target
    Karmely, M.
    Rubinstein, D. B.
    Pichinuk, E.
    Ziv, R.
    Benhar, I.
    Feng, N.
    Wreschner, D. H.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [28] MUC1 expression, splice variant and short form transcription (MUC1/Z, MUC1/Y) in prostate cell lines and tissue
    Schut, IC
    Waterfall, PM
    Ross, M
    O'Sullivan, C
    Miller, WR
    Habib, FK
    Bayne, CW
    BJU INTERNATIONAL, 2003, 91 (03) : 278 - 283
  • [29] Characterization of a new MUC1 monoclonal antibody (VU-2-G7) directed to the glycosylated PDTR sequence of MUC1
    Ryuko, K
    Schol, DJ
    Snijdewint, FGM
    von Mensdorff-Pouilly, S
    Poort-Keesom, RJJ
    Karuntu-Wanamarta, YA
    Verstraeten, RA
    Miyazaki, K
    Kenemans, P
    Hilgers, J
    TUMOR BIOLOGY, 2000, 21 (04) : 197 - 210
  • [30] Tumour immunotherapy against MUC1 expressing tumours using mannan MUC1
    Apostolopoulos, V
    Pietersz, GA
    Acres, B
    Osinski, C
    Thynne, G
    Xing, PX
    Karanikas, V
    Vaughan, HA
    Hwang, L
    Popovski, V
    Lees, C
    Ong, CS
    McKenzie, IFC
    BREAST CANCER - ADVANCES IN BIOLOGY AND THERAPEUTICS, 1996, : 315 - 320